Vistagen Therapeutics, Inc.
For the period ended Sep 10, 2026. Filed Sep 11, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 10, 2026 · Filed Sep 11, 2026
Use the contents to explore the available documents and sections.
Contents
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | VTGN | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging Growth Companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Acto
Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 10, 2026, Vistagen Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholders: (i) elected each of the four director nominees to the Company’s Board of Directors (the “Board”); (ii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers; and (iii) ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending March 31, 2027.
The matters voted upon at the 2026 Annual Meeting and the results of the voting by the Company’s stockholders are as follows:
Proposal No. 1 – Election of Directors
| For | Withheld | |
|---|---|---|
| Jon S. Saxe, J.D., LL.M.Chair and Independent Director | 7,354,923 | 1,141,965 |
| Ann M. Cunningham, MBAIndependent Director | 4,664,450 | 3,832,438 |
| Douglas J. Williamson, M.D.Independent Director | 7,382,907 | 1,113,981 |
| Shawn K. Singh, J.D.President, Chief Executive Officer and Director | 4,971,180 | 3,525,708 |
Members of the Board are elected by a plurality of the votes cast. Accordingly, each of the director nominees named above was elected to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders, or until her or his successor is elected and qualified.
Proposal No. 2 – Non-Binding Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.